Estrella Immunopharma reports positive phase 1 data for cancer therapy Feb 9, 2026 07:01AM
Estrella Immunopharma (ESLA) files for 9.24M share offering by selling stockholders Jan 16, 2026 05:10PM
Estrella Immunopharma (ESLA) files for 2.54M share offering by selling stockholders Dec 22, 2025 10:58AM
Estrella advances cancer therapy trial to phase II after safety review Dec 4, 2025 08:03AM
Estrella Immunopharma reports complete response in EB103 lymphoma trial Nov 3, 2025 10:02AM


Jun 5, 2025 08:03AM Estrella Immunopharma (ESLA) Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial
Jun 3, 2025 08:00AM Estrella Immunopharma (ESLA) Announces 2.33M Share Offering at $1.50/sh
Feb 21, 2025 08:32AM Estrella Immunopharma (ESLA) Completes First Dose Cohort in STARLIGHT-1 Trial, Receives Approval to Initiate Higher Dose Cohort
Sep 27, 2024 12:00PM Estrella Immunopharma (ESLA) Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS T-cells
Aug 14, 2024 12:00PM Estrella Immunopharma (ESLA) Appoints Hong Zhang as Board Chair